These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 2243507

  • 1. A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia.
    Stone RM, Spriggs DR, Dhawan RK, Arthur KA, Mayer RJ, Kufe DW.
    Leukemia; 1990 Dec; 4(12):843-7. PubMed ID: 2243507
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
    Grant S, Baker M, Bhalla K.
    Leukemia; 1993 Dec; 7(12):1933-8. PubMed ID: 8255091
    [Abstract] [Full Text] [Related]

  • 3. Prolonged high dose ARA-C infusions in acute leukemia.
    Spriggs DR, Robbins G, Arthur K, Mayer RJ, Kufe D.
    Leukemia; 1988 May; 2(5):304-6. PubMed ID: 3287017
    [Abstract] [Full Text] [Related]

  • 4. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP, Preisler HD, Slocum H, Rustum YM.
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [Abstract] [Full Text] [Related]

  • 5. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E.
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [Abstract] [Full Text] [Related]

  • 6. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
    Kreis W, Budman DR, Chan K, Allen SL, Schulman P, Lichtman S, Weiselberg L, Schuster M, Freeman J, Akerman S.
    Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
    [Abstract] [Full Text] [Related]

  • 7. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 8. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ, Griffin JD.
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [Abstract] [Full Text] [Related]

  • 9. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI, Weinberg KI, Sato JK, Lenarsky C, Willoughby ML, Coates TD, Ozkaynak MF, Parkman R.
    Cancer Res; 1989 Jan 01; 49(1):241-7. PubMed ID: 2908850
    [Abstract] [Full Text] [Related]

  • 10. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.
    Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322
    [Abstract] [Full Text] [Related]

  • 11. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M, Hohenlöchter B, Schulze-Westhoff P, Zimmermann M, Ritter J, Jürgens H, Boos J.
    Klin Padiatr; 1996 Jun 01; 208(4):151-9. PubMed ID: 8926681
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
    Kornblau SM, Cortes-Franco J, Estey E.
    Leukemia; 1993 Mar 01; 7(3):378-83. PubMed ID: 8445943
    [Abstract] [Full Text] [Related]

  • 14. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, Kowck R, Reaman GH, Sato JK.
    Clin Cancer Res; 1998 Jan 15; 4(1):45-52. PubMed ID: 9516951
    [Abstract] [Full Text] [Related]

  • 16. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.
    Leuk Res; 2008 Dec 15; 32(12):1830-6. PubMed ID: 18571721
    [Abstract] [Full Text] [Related]

  • 17. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 15; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 18. [Therapeutic effects of a combination of intermediate-dose cytosine arabinoside, adriamycin and vincristine in relapsed acute leukemia].
    Takahashi I, Yorimitsu S, Inagaki T, Sekito N, Hayashi N, Nishimura M, Aoyama S, Nakada H, Ohmoto E, Uchida K.
    Gan To Kagaku Ryoho; 1987 Feb 15; 14(2):485-9. PubMed ID: 3813576
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.